Nice lengthy story regarding the current ebola outbreak and 4430 as a potential future cure. Story reiterates that BCRX can't use the drug for the current outbreak and if FDA approval happens late next year Stonehouse said he would give it away for humanitarian purposes as BCRX main interest in stockpile.
BCRX has already been in contact with Drs. w/out Borders regarding 4430.
Good read, check it out.
TITLE: BioCryst Bets on New Ebola Drug to Fight Bioterror, Outbreak Threats
July 24, 2014
When do they start and where will they be (Multiple locations? Germany again?)
Will German subjects from the 1st trial be among the subjects this time?
When do we expect to hear results?
you bet map, and FYI, just because we might get bought out, doesn't mean the people who work at BCRX will loose their jobs. RDEA still exists at AZN. it's just a matter of who signs the checks…
As I said before, I don't think BCRX is in the market to be bought but this may be driving the pps along with expected positive updates on the pipeline on Aug 5th cc.
Hereditary Angioedema (HAE) Conference
Date:September 19-20, 2014
Location:San Diego, California
Description:Anticipated goals and use of results: 1) Organize and conduct a conference that is thematically focused on growing and extending knowledge in HAE; and which become progressively more ambitious over time, reflecting the anticipated advances in research...
German chemicals and drugs company Merck KGaA is in the market for mid-size acquisitions to bolster its pharmaceuticals division, the head of that unit told Swiss business paper Finanz und Wirtschaft.
Asked whether Merck was planning to go on a buying spree, Stefan Oschmann, the head of the company's pharma unit was quoted as saying: "Yes we are open to mid-size acquisitions," adding that the company was looking into potential targets in areas such as oncology and immunology.
"We cannot and will not buy a giant biotech or pharma competitor," Oschmann said.
Merck's Chief Executive Karl-Ludwig Kley had said in May the company could join a deal frenzy sweeping the pharmaceutical sector and that he was ready to take "ambitious steps".
That was shortly after buying Britain's AZ Electronic Materials for $2.6 billion.
Oschmann said Merck KGaA's biosimilar business, which makes copies of biotech medicines, was making good progress.
Khan, a Sierra Leonean virologist credited with treating more than 100 Ebola victims, has been transferred to a treatment ward run by medical charity Medecins Sans Frontieres, according to the statement released late on Tuesday by the president's office.
Health Minister Miatta Kargbo called Khan a national hero and said she would "do anything and everything in my power to ensure he survives".
Khan told Reuters in late June that he was worried about contracting Ebola. "I am afraid for my life, I must say, because I cherish my life," he said in an interview, showing no signs of ill health at the time.
"Health workers are prone to the disease because we are the first port of call for somebody who is sickened by disease. Even with the full protective clothing you put on, you are at risk."
Three days ago, three nurses working in the same Ebola treatment centre alongside Khan died from the disease.
Just tell the Dr. to wait a until next year when 4430 goes through human safety trials...hang on. Yes, ridiculous. If he dies was it Ebola or politics?
"Stateside deal with someone to market Peramivir"....
or whatever they're going to call it :-/
This close to approval (in biotech time) I'm sure they're working on the marketing / sales plan...would like to hear more on Aug. 5th.
I am waiting for you to tell the herd here you have closed your position and do not like the stock sometime in the next week.
BioCryst submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S.A.
According to the company, Peramivir may address unmet needs in the treatment of influenza.
Since the drug has been given Fast Track Status, it is expected that it will be approved by the FDA by August 20, 2014
Source: Pelagia Research Library
New chemical entities of future for infectious diseases